Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed) (353369)

    From US Department of Health & Human Services: National Institutes of Health (NIH)

    The National Institutes of Health (NIH), a part of the U.S. Department of Health and Human Services, is the nation’s medical research agency — making important discoveries that improve health and save lives.

    Type of Support

    Overview

    The grant program aims to fund efficacy studies in established rare disease preclinical models to demonstrate that a proposed therapeutic agent is ready for further development. It supports studies on therapeutic agents, including small molecules, biologics, or biotechnology-derived products, focusing on preclinical efficacy along with pharmacodynamic and pharmacokinetic studies. The objective is to advance therapeutic development for various rare diseases, encouraging projects to reach a stage that would attract further investment for full Investigational New Drug (IND) application development or progression to clinical trials, especially in cases of repurposing or repositioning existing treatments.

    Eligibility

    Organization's Location
    mollit duis, id amet, sint fugiat, et fugiat, laborum sint, consectetur aliqua
    Program Location
    cupidatat quis fugiat amet enim officia cillum nulla veniam reprehenderit
    Organization Type
    up to 275K

    Submission

    Schedule
    Step 1: sit pariatur irure
    Application deadline
    Mar 15, 2025
    Step 2: reprehenderit eiusmod (do magna)

    Similar grants